2025-01-03 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Report

**1. Performance Comparison & Divergence:**

Eli Lilly and Co. (LLY) is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products.

LLY's cumulative return is significantly higher than the S&P 500 (VOO) over the observed period.  The difference in cumulative returns is 445.7%.  This places LLY at the 71.4th percentile of its historical range relative to the S&P 500, indicating strong outperformance.  The provided alpha values of 0.0 throughout the periods suggest that the outperformance is not solely attributable to market movements, requiring further investigation beyond this data.


**2. Recent Price Movement:**

* **Closing Price:** $777.77
* **5-Day Moving Average:** $780.18
* **20-Day Moving Average:** $789.67
* **60-Day Moving Average:** $822.06

The current price is below all three moving averages, suggesting a potential short-term downtrend.


**3. Technical Indicators & Expected Return:**

* **RSI:** 42.44 - This suggests the stock is approaching oversold territory, but not definitively so.
* **PPO:** 0.08 - A slightly positive PPO indicates some bullish momentum, although it is weak.
* **Relative Strength Change (20-day):** -1.9% - This indicates a recent slight weakening in relative strength.
* **Expected Return (2+ years):** 118.7% -  This indicates a significant outperformance of the S&P 500 is expected over the long term, assuming the current trends continue.  This should be treated cautiously, as expected returns are not guarantees.  The current price of $777.77 doesn't trigger any flags about abrupt price changes.


**4. Recent Earnings Analysis:**

The provided data shows significant variability in quarterly EPS, with a notable drop in the Q4 2023, followed by increases in subsequent quarters. Revenue has generally shown an increasing trend, but with some minor fluctuations.  The substantial increase in EPS from Q4 2023 to Q1 2024 is noteworthy.  Without access to earnings expectations, we cannot determine if these results beat or missed forecasts.

* **Q4 2023:** EPS decreased significantly compared to previous quarters.
* **Q1 2024:** Significant EPS increase compared to Q4 2023.
* **Q2 2024:** Continued high EPS, indicating consistent profitability.
* **Q3 2024:** EPS and revenue show signs of continued positive performance.


**5. Financial Information Analysis:**

The financial data exhibits a generally positive trend.  Revenue remains relatively stable and robust, with profit margins consistently high (above 80%).  Equity has grown, but ROE fluctuates significantly, possibly indicating variations in profitability and capital utilization strategies across quarters. The negative ROE in Q3 2023 is a point that requires further investigation to determine the underlying causes.


**6. News and Recent Issues:**

This section requires information from recent news sources.  Without access to real-time news feeds, I cannot provide analysis on recent earnings news, market outlook, or analyst opinions.


**7. Overall Analysis:**

LLY shows signs of strong long-term growth potential, significantly outperforming the S&P 500 in the past.  However, recent price action suggests a potential short-term slowdown.  While the high expected return is promising, investors should consider the volatility observed in the EPS and ROE.  Further analysis is required to understand the factors driving the substantial changes in quarterly EPS and the negative ROE in Q3 2023.  The lack of current news and analyst opinions prevents a complete assessment of the current market sentiment and future prospects.  Detailed research into the reasons behind the fluctuating ROE and the significant EPS changes, coupled with current market analysis, is needed before drawing definitive conclusions.

**8. Disclaimer:**  This report is based solely on the provided data.  It does not constitute financial advice.  Investing in the stock market involves inherent risks, and past performance is not indicative of future results.  Always conduct thorough due diligence and consider consulting a financial advisor before making any investment decisions.
